2023
DOI: 10.1080/14760584.2023.2188950
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 29 publications
0
4
0
Order By: Relevance
“…After booster vaccination, VE improved considerably, reaching about 70%. 13 , 15 , 24 Nevertheless, some studies found an increased risk of infection of 14% after ten weeks of vaccination 17 and an increased risk of infection beyond 20 weeks when the vaccine’s efficacy declined by more than 20%. 25–27 We also noticed that most of the patients we included were individuals vaccinated for more than 140 days.…”
Section: Discussionmentioning
confidence: 99%
“…After booster vaccination, VE improved considerably, reaching about 70%. 13 , 15 , 24 Nevertheless, some studies found an increased risk of infection of 14% after ten weeks of vaccination 17 and an increased risk of infection beyond 20 weeks when the vaccine’s efficacy declined by more than 20%. 25–27 We also noticed that most of the patients we included were individuals vaccinated for more than 140 days.…”
Section: Discussionmentioning
confidence: 99%
“…The first report of mRNA vaccine efficacy was published in Israel [16]. Since then, there have been variations in the viral epidemic strains, but a certain level of efficacy has been maintained [14,15,17,18]. Furthermore, several studies, including the results of a meta-analysis, have shown that vaccination reduces not only COVID-19-related but also allcause mortality [13][14][15].…”
Section: Discussionmentioning
confidence: 99%
“…17 This study found the VE against infection and hospitalization in those ages 16-64 years in Japan to be 54.7% and 84.9%, respectively between October 1, 2022 and February 28, 2023. 18 Thus, the model base case assumes VEs of 55% and 85% against infection and hospitalization (i.e. severe disease) respectively.…”
Section: Model Inputs: Fall 2023 Covid-19 Vaccine Coveragementioning
confidence: 99%